Quick Takeaways
- TFF Pharmaceuticals, Inc. has 15 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 15 Insiders of TFF Pharmaceuticals, Inc.
- Location
- Austin, TX
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 May 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
TFF Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Carlson Capital, L.P. | 10%+ Owner | $4,198,493 | Filing P/S | 15 Aug 2023 | ||
| Malcolm P. Fairbairn | Director | $519,876 | Mixed | 19 May 2021 | ||
| Harlan F. Weisman | President and CEO, Director | $347,373 | Mixed | 03 Jul 2024 | ||
| Zamaneh Mikhak | Chief Medical Officer | $61,005 | Mixed | 03 Jul 2024 | ||
| Robert S. Mills | Director | $24,989 | Mixed | 03 Jul 2024 | ||
| Kirk Allen Coleman | Chief Financial Officer | $22,109 | Mixed | 03 Jul 2024 | ||
| Stephen Rocamboli | Director | $17,165 | Mixed | 03 Jul 2024 | ||
| Glenn R. Mattes | President and CEO, Director | $16,839 | Mixed | 16 May 2022 | ||
| Brandi Roberts | Director | $11,159 | Mixed | 03 Jul 2024 | ||
| Catherine C. Lee | Director | $2,013 | Mixed | 03 Jul 2024 | ||
| Thomas B. King | Director | $1,838 | Mixed | 03 Jul 2024 | ||
| Michael A. Patane | Director | $1,393 | Mixed | 18 Apr 2024 | ||
| Christopher Cano | Chief Operating Officer | Mixed | 22 Sep 2021 | |||
| Randy H. Thurman | Director | Mixed | 29 Sep 2022 | |||
| Aaron G.l. Fletcher | Director | Mixed | 29 Dec 2022 |
Top shareholders of TFF Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Carlson Capital, L.P. |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
10,129,000
mixed-class rows
|
$4,198,493 | — | 15 Aug 2023 | |
| Malcolm P. Fairbairn |
3/4/5
|
Director |
—
class O/S missing
|
1,327,568
|
$519,876 | — | 19 May 2021 | |
| Harlan F. Weisman |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
914,542
mixed-class rows
|
$347,373 | — | 03 Jul 2024 | |
| Zamaneh Mikhak |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
165,968
mixed-class rows
|
$61,005 | — | 03 Jul 2024 | |
| Robert S. Mills |
3/4/5
|
Director |
—
mixed-class rows
|
66,977
mixed-class rows
|
$24,989 | — | 03 Jul 2024 | |
| Kirk Allen Coleman |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
66,643
mixed-class rows
|
$22,109 | — | 03 Jul 2024 | |
| Stephen Rocamboli |
3/4/5
|
Director |
—
mixed-class rows
|
46,997
mixed-class rows
|
$17,165 | — | 03 Jul 2024 | |
| Glenn R. Mattes |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
43,000
|
$16,839 | — | 16 May 2022 | |
| Brandi Roberts |
3/4/5
|
Director |
—
mixed-class rows
|
31,663
mixed-class rows
|
$11,159 | — | 03 Jul 2024 | |
| Catherine C. Lee |
3/4/5
|
Director |
—
mixed-class rows
|
6,722
mixed-class rows
|
$2,013 | — | 03 Jul 2024 | |
| Thomas B. King |
3/4/5
|
Director |
—
mixed-class rows
|
6,276
mixed-class rows
|
$1,838 | — | 03 Jul 2024 | |
| Michael A. Patane |
3/4/5
|
Director |
—
mixed-class rows
|
135,998
mixed-class rows
|
$1,393 | — | 18 Apr 2024 | |
| Christopher Cano |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
200,000
|
— | — | 22 Sep 2021 | |
| Randy H. Thurman |
3/4/5
|
Director |
—
class O/S missing
|
84,670
|
— | — | 29 Sep 2022 | |
| Aaron G.l. Fletcher |
3/4/5
|
Director |
—
class O/S missing
|
33,475
|
— | — | 29 Dec 2022 |
Recent Insider Transactions by Companies or Individuals for TFF Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.